Mengjie Li1, Lap Ah Tse2, Wing-Cheong Chan3, Chi-hei Kwok4, Siu-lan Leung5, Cherry Wu6, Wai-cho Yu7, Ignatius Tak-sun Yu1, Chloe Hui-Tung Yu8, Feng Wang1, Hyuna Sung9, Xiaohong R Yang9. 1. JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, China. 2. JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, China. Electronic address: shelly@cuhk.edu.hk. 3. Department of Surgery, North District Hospital, Hong Kong SAR, China. 4. Department of Oncology, Princess Margaret Hospital, Hong Kong SAR, China. 5. Department of Surgery, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China. 6. Department of Pathology, North District Hospital, Hong Kong SAR, China. 7. Department of Medicine, Princess Margaret Hospital, Hong Kong SAR, China. 8. Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. 9. Genetic Epidemiology Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, United States.
Abstract
PURPOSE: Experimental studies implicate tea and tea polyphenols may be preventive against breast cancer, but evidence from epidemiological studies has been inconsistent. We conducted a hospital-based case-control study to evaluate the role of tea especially green tea in breast cancer etiology. METHODS: We consecutively recruited 756 incident breast cancer cases and 789 hospital controls who had completed information on tea consumption. We calculated odds ratios (ORs) for tea consumption using unconditional multivariable logistic regression. We further conducted stratified analyses to assess whether the effect of tea consumption varied by menopausal status and estrogen receptor (ER). RESULTS: Overall, 439 (58.1%) breast cancer cases and 434 (55.0%) controls reported habits of regular tea drinking, showing an adjusted OR of 1.01 (95%CI: 0.78-1.31) and 1.20 (95%CI: 0.80-1.78) for any tea and green tea drinking, respectively. Regular tea drinking was significantly associated with a lower risk for breast cancer in pre-menopausal women (OR=0.62, 95%CI: 0.40-0.97) but an increased risk in post-menopausal women (OR=1.40, 95%CI: 1.00-1.96). The positive association among postmenopausal women was strongest among ER-negative green tea drinkers (OR=2.99, 95% CI: 1.26-7.11). CONCLUSIONS:Tea or green tea drinking was not associated with overall breast cancer risk, which may be masked by the differential effect in pre- and post-menopausal women.
RCT Entities:
PURPOSE: Experimental studies implicate tea and teapolyphenols may be preventive against breast cancer, but evidence from epidemiological studies has been inconsistent. We conducted a hospital-based case-control study to evaluate the role of tea especially green tea in breast cancer etiology. METHODS: We consecutively recruited 756 incident breast cancer cases and 789 hospital controls who had completed information on tea consumption. We calculated odds ratios (ORs) for tea consumption using unconditional multivariable logistic regression. We further conducted stratified analyses to assess whether the effect of tea consumption varied by menopausal status and estrogen receptor (ER). RESULTS: Overall, 439 (58.1%) breast cancer cases and 434 (55.0%) controls reported habits of regular tea drinking, showing an adjusted OR of 1.01 (95%CI: 0.78-1.31) and 1.20 (95%CI: 0.80-1.78) for any tea and green tea drinking, respectively. Regular tea drinking was significantly associated with a lower risk for breast cancer in pre-menopausal women (OR=0.62, 95%CI: 0.40-0.97) but an increased risk in post-menopausal women (OR=1.40, 95%CI: 1.00-1.96). The positive association among postmenopausal women was strongest among ER-negative green tea drinkers (OR=2.99, 95% CI: 1.26-7.11). CONCLUSIONS:Tea or green tea drinking was not associated with overall breast cancer risk, which may be masked by the differential effect in pre- and post-menopausal women.
Authors: Sze Wan Hung; Yiran Li; Xiaoyan Chen; Kai On Chu; Yiwei Zhao; Yingyu Liu; Xi Guo; Gene Chi-Wai Man; Chi Chiu Wang Journal: Front Pharmacol Date: 2022-07-04 Impact factor: 5.988
Authors: Fatima Ez-Zahra Amrati; Mohammed Bourhia; Meryem Slighoua; Samir Ibnemoussa; Ahmed Bari; Riaz Ullah; Amal Amaghnouje; Francesca Di Cristo; Mohammed El Mzibri; Anna Calarco; Laila Benbacer; Dalila Bousta Journal: Evid Based Complement Alternat Med Date: 2020-03-19 Impact factor: 2.629
Authors: Dongyu Zhang; Hazel B Nichols; Melissa Troester; Jianwen Cai; Jeannette T Bensen; Dale P Sandler Journal: Int J Cancer Date: 2020-02-04 Impact factor: 7.316